Introduction
Mitochondria are unique organelles within the cell. They participate in the generation of metabolic energy, as well as in the maintenance of calcium and redox homeostasis (Boveris and Chance, 1973; Clapham, 1995; Rolfe and Brown, 1997) . Besides, within this highly compartmentalized organelle a number of biosynthetic reactions take place. In addition to their contribution to cellular metabolism, mitochondria play a key role in the regulation of cell death (reviewed by Green and Reed, 1998; Kroemer and Reed, 2000) . The promise that mitochondria may provide new opportunities for therapeutic intervention in cancer stems from several reasons. The fact that mitochondrial membrane permeabilization is a 'point of no return' (Kroemer, 2002) and that once it occurs cells die by apoptosis or necrosis, makes this organelle in principle a robust target of choice. In addition, the rich repertoire of mitochondrial proteins and the essential requirement of the membrane permeability barrier for proper organelle function present us with an array of opportunities for drug development. However, mitochondria are at the crossroad of life and death decisions in most cell types. Therefore, the challenge lies in choosing targets or devising smart targeting strategies that will lead to selective anticancer effects.
Over the years, studies from laboratories working in various aspects of mitochondrial physiology have revealed alterations in number, ultrastructure, proteome and activity of mitochondria in tumor cells (Figure 1 ). Accordingly, one approach to the development of therapies for the treatment of cancer is to exploit some of the differences existing between mitochondria in normal and malignant cells in order to selectively target the latter. In this case, identifying those tumor-specific mitochondrial traits and molecular targets are the key to maximize the therapeutic index of the mitochondriatargeted anticancer agents. Alternatively, there are ways to selectively disable tumor cell mitochondria that do not rely on intrinsic differences in this organelle between normal and malignant cells. In this case, selective delivery of the mitochondriotoxic agent through overexpressed receptors at the cancer cell surface becomes a requirement sine qua non; we will revisit this point later in this discussion.
This review attempts to summarize the current understanding of well-established mitochondrial drug targets with an emphasis on novel approaches to the development of mitochondrial toxins for the treatment of cancer.
Agents targeting the intrinsic mitochondrial apoptotic pathway
As mentioned earlier, a variety of apoptotic stimuli can trigger mitochondrial outer membrane permeabilization (MOMP). This event results in the release from the mitochondrial intermembrane space into the cytosol of several factors, collectively known as intermembrane space (IMS) proteins, including cytochrome c, endonuclease G, apoptosis inducing factor (AIF) and smac/ DIABLO (Ravagnan et al., 2002; van Loo et al., 2002; Newmeyer and Ferguson-Miller, 2003) . In turn, they set in motion a series of biochemical events that mediate the execution phase of the cell death program ultimately leading to the degradation of key house-keeping proteins by caspases and of genomic DNA by endonucleases. This process is accompanied by loss of mitochondrial membrane potential, depletion of the cellular ATP pool and increase in reactive oxygen species levels that altogether contribute to the cell demise. The fact that MOMP represents a commitment point in the process of cell death has prompted efforts to develop agents capable of eliciting it. This is a fast growing area in terms of diversity and number of lead compounds. Mitochondrial outer membrane permeabilization is a complex process that involves numerous molecular players and has provided a series of druggable targets. It is generally believed that MOMP can occur by two distinct mechanisms, one involving the Bcl-2 family of proteins, the other through opening of the permeability transition pore (PTP). However, some of the proteins implicated have been shown to participate in both Figure 1 Mitochondrial alterations in cancer. In the classical multistep model of neoplastic transformation the initial states of tumorigenesis are characterized by a high degree of genomic instability and a relaxation of cell cycle control mechanisms. During this early phase the extreme conditions of the tumor microenvironment (hypoxia, acidosis and nutrient deprivation) select for phenotypes that confer emerging cells with a significant growth advantage. A common adaptive mechanism to cope with environmental constraints results in changes of the energy metabolism of cancer cells, which are usually associated with alterations in the mitochondrial functions. Some of these 'tumor-specific' mitochondrial features could be exploited for the development of selective anticancer therapeutics. (Csordas et al., 2002; Scorrano et al., 2002) .
Therapeutic strategies targeting the Bcl-2 family In the first model, the process of mitochondrial membrane permeabilization starts at the level of the outer membrane and is regulated by the pro-and antiapoptotic members of the Bcl-2 family (Cory and Adams, 2002; Borner, 2003; Kuwana and Newmeyer, 2003) . These proteins possess one or more Bcl-2 homology (BH1 through BH4) domains. The antiapoptotic members of this clan, including Bcl-2, Bcl-xL and Mcl-1, usually contain all BH domains and inhibit MOMP. On the other hand, the proapoptotic members can be divided into multidomain members (Bax, Bak and Bok) that possess BH1-3 domains and 'BH3-only' members that as their name implies only possess the BH3 domain. Mitochondrial outer membrane permeabilization results from the activity of the proapoptotic, multidomain proteins Bax and Bak, which can be triggered by heterodimerization with 'activating' BH3-only proteins such as Bim and Bid (Korsmeyer et al., 2000) . Bax and Bak are antagonized by the 'derepressor' branch of the BH3-only group, including Bad, Bik and PUMA.
High levels of Bcl-2 and Bcl-xL expression have been observed in a variety of hematologic malignancies as well as solid tumors, and overexpression of these proteins has been correlated with chemoresistance and radioresistance of cancer cells (Miyashita and Reed, 1993; Reed, 1999; Johnstone et al., 2002; Kitada et al., 2002; Konopleva et al., 2002; Jameel et al., 2004) . The stoichiometric balance between pro-and antiapoptotic family members seems to be a critical factor that regulates apoptosis induction, which may explain in part the increased sensitivity of cancer cells to inhibitors targeting this category of proteins. To date, several strategies have been employed to block the activity of the antiapoptotic proteins. Antisense oligonucleotides have been designed to block their expression. The pioneering studies focused on Bcl-2 (Reed et al., 1990a (Reed et al., , 1990b . Since then, a series of antisense oligonucleotides directed against Bcl-2 and Bcl-xL have been synthesized. So far oblimersen (Genasense), an 18-mer phosphorothioate antisense oligonucleotide targeted to the Bcl-2 mRNA, is the most advanced agent of this class in the clinic. In preclinical studies, oblimersen as a single agent had a cytostatic effect on growth of human breast and melanoma xenograft transplants and showed a synergistic effect in combination with dacarbazine (Jansen et al., 1998) . Unfortunately, no increase in survival of melanoma patients treated with oblimersen monotherapy was registered in the Phase III trial. However, the results showed a slow down in disease progression consistent with the observations in rodent models. In a small dose-escalation trial in patients with Bcl-2 positive advanced malignant melanoma the oblimersen-dacarbazine combination was well tolerated and led to several antitumor responses (Jansen et al., 1998) . Further trials in other cancer indications and in combination with additional standard cytotoxic agents are anticipated.
Another approach to trigger MOMP is to target the dimerization interface between antiapoptotic Bcl-2 members and proapoptotic relatives. Mutational analysis has determined the importance of the BH3 domain for dimerization of Bcl-2 proteins (Hanada et al., 1995; Zha et al., 1996) . Based on this notion, a series of peptidomimetic small molecules that block the heterodimerization of pro-and antiapoptotic family members have been identified. Antimycin A previously characterized as an inhibitor of the electron transport chain has been shown to bind the BH3 domain of Bcl-xL and to induce apoptosis in cells overexpressing Bcl-2 and BclxL (Tzung et al., 2001 ). An enantiomer devoid of the inhibitory activity on respiration was still capable of inducing cell death in the same context demonstrating that these are two separate properties of antimycin A. HA14-1, identified by computational chemistry using the known 3D-structure of Bcl-2 (Wang et al., 2000a) was shown to induce apoptosis in malignant cells, and this effect could be blocked by caspase inhibitors. Gossypol is a natural polyphenolic compound from cottonseed with known anticancer activity. The activity of (À)-gossypol has been associated with numerous mechanisms of action, including a direct effect on mitochondria (Benz et al., 1990) . Interestingly, (À) Gossypol has been shown to bind both Bcl-2 and BclxL with relatively high affinity (Kitada et al., 2003) . In recent studies, (À)-gossypol enhanced the efficacy of radiation treatment on human hormone-refractory prostate xenograft transplants in mice (Xu et al., 2005) . Further studies will help to address whether (À)-gossypol-mediated radiosensitization is linked to inhibition of Bcl-2 and Bcl-xL. High-throughput and computational screens have led to the identification of several lower affinity compounds with Bcl-2-and/or Bcl-xL-binding activity that may represent promising chemical scaffolds (Degterev et al., 2001; Enyedy et al., 2001) . More recently, a compound that binds the hydrophobic BH3-binding groove of Bcl-2 with high affinity was developed using SAR (structure-activity relationship) by NMR (Oltersdorf et al., 2005) . ABT-737 induces apoptosis of some cancer cell lines, including lymphoma and small-cell lung cancer (SCLC) and it enhances the effects of radiation and chemotherapy against other cancer types. In vivo, ABT-737 induced complete regression of SCLC xenografts. This small molecule is currently in Phase I clinical trial. Among the recent additions to the list of compounds designed to interfere with the heterodimerization of Bcl-2 as well as Bcl-xL and proapoptotic proteins are the terphenyl-based BH3 proteomimetics (Yin et al., 2005) . These molecules are synthetic mimics of a-helices. A library of terphenyl derivatives that mimic the helical region of the Bak BH3 was prepared using a synthetic sequential strategy. The most potent molecule in the group exhibited an in vitro K i in the high nanomolar range and was capable of disrupting the Bcl-xL-Bax interaction in cells. Additional studies will be required to determine the antitumor efficacy of this interesting class of compounds.
In addition to small molecules, BH3 peptides that bind to the BH3-binding pocket in Bcl-2, Bcl-xL and Mcl-1 have been engineered. One obvious advantage of peptides is their ability to bypass the multidrug resistance due to drug efflux mechanisms commonly observed in tumor cells. On the other hand, some of the limitations to the use of peptides as potential therapeutic agents are solubility, which depends on the polypeptide sequence, stability and cell permeability. However, a number of clever approaches have been applied to generate BH3 peptide prototypes that overcome some of these barriers. For instance, the BH3 domains of Bax and Bak have been fused to the membrane translocation domain of Drosophila Antennapedia and herpex simplex virus VP22, respectively (Vieira et al., 2002; Brewis et al., 2003) . In addition, BH3 peptides have been modified with an arginine membrane-transduction domain (Goldsmith and Hogarty, 2005) or conjugated to decanoic acid (Wang et al., 2000b) . To increase peptide stability, a chemical strategy termed hydrocarbon stapling was used to create protease resistant BH3 peptides (Walensky et al., 2004) . The generated stapled peptides, termed SAHBs for 'stabilized alpha-helix of Bcl-2 domains', induced apoptosis of Jurkat cells and inhibited growth of human leukemia xenografts. To date the results are encouraging. All these peptides are capable of binding Bcl-2 and Bcl-xL in vitro. However, less is known about their activities once internalized. In the future, studies designed to follow these peptides in cells will help to gain a better understanding about their trafficking and mechanism of action.
Compounds that target the permeability transition pore Mitochondrial membrane permeabilization can occur by a second mechanism known as permeability transition (PT) (Figure 2b ). Permeabilization of the inner mitochondrial membrane to solutes smaller than 1.5 kDa is preceded by the formation of a protein megapore complex that spans the inner and outer mitochondrial membranes, known as the PTP (Bernardi et al., 1999; Kroemer et al., 1998) . The identity and exact stoichiometry of all the members that constitute the cyclosporin A (CsA)-sensitive PTP complex is still under investigation (Forte and Bernardi, 2005; Zamzami et al., 2005) . The core of this mitochondrial pore is thought to be constituted by the voltage-dependent anion channel (VDAC) located in the outer membrane, and the bongkrekic acid-sensitive adenine nucleotide translocase (ANT) located in the inner membrane. Among the additional constituents, the peripheral-type benzodiazepine receptor (PBR) and hexokinase are located at the surface of mitochondria where they interact with VDAC, creatine kinase sits in the IMS and cyclophilin D, a peptidyl-prolyl isomerase target of CsA action, resides in the matrix. Creatine kinase and cyclophilin D directly interact with ANT and facilitate PT. Conditions that stimulate the release of calcium from the endoplasmic reticulum resulting in mitochondrial calcium overload or that promote the oxidation of vicinal cysteine residues in ANT lead to the PTP opening. As a result, the influx of water and ions into the matrix causes matrix swelling and loss of mitochondrial membrane potential. Ultimately, the burst of the outer mitochondrial membrane results in the release of the IMS proteins into the cytosol.
Therapeutic strategies based on targeting PTP components to induce mitochondrial membrane permeabilization hold, as mentioned earlier, the potential to circumvent conventional resistance to apoptosis induction. The fact that several compounds triggering PT are selectively toxic to tumor cells suggests that the threshold to induce this state may be lower in malignant than in normal cells. This phenomenon could be due, among other reasons, to the overexpression of some of the PTP components, to the prevalence of tumor-specific pore component isoforms and to the dependency of the cancer cells on those factors for their survival. Additionally, the altered redox balance of cancer cell mitochondria may affect the activity of thiol-containing pore proteins, altering their behavior (Chernyak and Bernardi, 1996; Stadtman, 2001) . The arguments supporting each of the PTP proteins as valuable therapeutic targets are diverse. Noteworthy, proteins like PBR, creatine kinase and hexokinase have in addition to their connection to the apoptosis machinery, important roles in metabolic and biosynthetic pathways that are beyond the scope of this review. Thus, targeting some of the PTP components will affect the pore activity and at the same time may interfere with other cellular processes. Whether these effects cooperate to induce PT and eventually MOMP is not completely understood. As it will become evident in the following paragraph, there are also chemical agents that are known to trigger PT by causing opening of the PTP even though their exact target of action within the pore complex remains uncertain. Among the PTP complex component, ANT has been considered a potential target for therapeutic intervention. There are four ANT isoforms (Halestrap and Brenner, 2003; Dolce et al., 2005) . Adenine nucleotide translocase1 expression is mainly restricted to heart and skeletal muscle. Expression of the recently identified ANT4 isoform has been shown to be low in most human adult tissues (Dolce et al., 2005) . Interestingly, selective expression of ANT4 in murine pluripotent and germline stem cells, as well as transcriptional silencing in somatic cells has been reported to be controlled by DNA methylation (Rodic et al., 2005) . ANT3 is ubiquitously expressed, whereas ANT2 is merely confined to highly proliferating myoblasts and malignant cells. In fact, ANT2 expression has been recently proposed to be essential for cancer cell glycolysis (Chevrollier et al., 2005) . It is still not clear whether expression of the different isoforms has an impact on PTP sensitivity to opening. The ANT polypeptides contain vicinal cysteines that have been implicated in modulating its activity (Majima et al., 1994 (Majima et al., , 1995 . Thiol crosslinking agents such as phenyl arsenoxide (PAO) Nonetheless, owing to the presence of vicinal cysteines in a variety of proteins these compounds are too toxic to be considered as therapeutic leads. The trivalent arsenical peptide GSAO (4-(N-(S-glutathionylacetyl) amino)phenylarsenoxide) is a derivative of PAO that has been shown to block proliferation of tumor endothelial cells due to a similar thiol crosslinking activity (Don et al., 2003) . 4-(N-(S-glutathionylacetyl)amino)phenylarsenoxide was able to inhibit tumor angiogenesis in vivo. However, this compound was also reported to affect vicinal thiols in other proteins including protein tyrosine phosphatases that affect phosphorylation of focal adhesion kinase (FAK) and paxillin. Plans for clinical trials with GSAO were announced and the results may help to validate the viability of crosslinking approaches for ANT inhibition. Betulinic acid is a naturally occurring pentacyclic triterpenoid that exhibits selective cytotoxicity against neuroectodermal and epithelial tumor cells and demonstrated an inhibitory effect on growth of human melanoma and ovarian xenografts in mice (Eiznhamer and Xu, 2004) . Betulinic acid has been shown to induce PT on isolated mitochondria (Fulda et al., 1998) . The direct target of action within the organelle remains undefined, but ANT is the most suspected candidate. The naphthalene carboxylic acid CD437 is a synthetic retinoid acid receptor gamma agonist that induces apoptosis of alltrans retinoic acid resistant leukemia cells (Hsu et al., 1997) . The activity of CD437 does not seem to be mediated by binding to retinoid nuclear receptors but rather by a direct effect on ANT and PTP activity (Marchetti et al., 1999; Belzacq et al., 2001) . Inhibition of proliferation of melanoma cell lines and xenograft transplants in mice in response to CD347 treatment has also been reported (Schadendorf et al., 1996) . Lonidamine is a dichlorinated derivative of an indazole-3-carboxylic acid that has been shown to affect ANT activity in reconstituted proteoliposomes and PTP activity in isolated mitochondria (Ravagnan et al., 1999; Belzacq et al., 2001) . In addition to inhibition of ANT, the antitumor activity of lonidamine has been linked to inhibition of hexokinase and consequently with an effect on glucose metabolism in malignant cells. Lonidamine has been launched in Italy for the treatment of lung, prostate, breast and cervix cancers. In other countries, Phase II/III clinical trials for breast, ovarian and lung cancer as a single agent are still underway. The benefit of lonidamine in combination with chemotherapy is also being evaluated. Arsenic trioxide (TRISENOX) is currently used for the treatment of acute promyelocytic leukemia (APL). The anticancer activity of this compound has been associated with a direct effect on ANT (Kroemer and de The, 1999; Belzacq et al., 2001) . Arsenic trioxide has also been shown to inhibit VDAC, to affect oxidative phosphorylation and to stimulate production of reactive oxygen species. Whether the activity of arsenic trioxide is mainly due to the inhibition of any particular target remains a subject of investigation. However, it is clear that it triggers PT, cytochrome c release and death of leukemia cells. More recently, arsenic trioxide has entered clinical trials in combination with ascorbic acid for the treatment of resistant multiple myeloma.
Peripheral-type benzodiazepine receptor is generally viewed as an antiapoptotic protein. Overexpression of PBR has been reported in both cancer cell lines and malignant tissues. High levels of this protein correlate with tumor aggressiveness, and PBR ligands were shown to induce apoptosis of cancer cell lines (Katz et al., 1990; Miettinen et al., 1995; Venturini et al., 1999; Beinlich et al., 2000; Maaser et al., 2001; Sutter et al., 2002) . The isoquinoline carboxamide PK11195 and the indoleacetamide derivative FGIN-1-27 are two examples of potent PBR antagonists. In addition to its antitumor activity as a single agent, the pharmacological properties of PK11195 make it an attractive candidate for combination strategies. PK11195 blocks P-glycoprotein-mediated drug efflux and increases the efficacy of several chemotherapeutic agents (Walter et al., 2005) . Of note, in addition to the effect on P-glycoprotein, the chemosensitizing activity of PK11195 has been associated also with a direct effect on mitochondria independent of PBR (Gonzalez-Polo et al., 2005) . The synthetic PBR ligand RO5-4865 enhanced apoptosis induced by anti-CD95 receptor antibodies in a variety of malignancies, and resulted in chemosensitization when administered in combination with etoposide and ifosfamide in two SCLC xenograft transplant models (Decaudin et al., 2002) . Peripheral-type benzodiazepine receptor ligands have also been conjugated to the cytotoxic compound gemcitabine as a means to improve the selectivity of the antitumor agent (Guo et al., 2001) . This strategy proved to be successful against brain tumor xenografts.
Overxepression of hexokinase II occurs in a variety of highly aggressive cancers that exhibit elevated rates of glycolysis (Dang and Semenza, 1999; Pedersen et al., 2002) . Nonhydrolizable glucose analogs have demonstrated antitumor activity, providing strong support for hexokinase as a therapeutic target. In addition, as previously mentioned hexokinase is a target of the antitumor agent lonidamine. Hexokinase is believed to be an integrator of metabolism and mitochondria bioenergetics, facilitating glucose utilization and inhibiting cell death. In tumor cells, the enzyme is usually constitutively associated with VDAC on the outer mitochondrial membrane through its N-terminal hydrophobic domain (Linden et al., 1982; Pastorino and Hoek, 2003) . These features of hexokinase II are being exploited to develop selective strategies to neutralize the enzyme by either promoting its release from mitochondria or by blocking its activity. The compound 3-bromopyruvate is an inhibitor of mitochondrially bound hexokinase, capable of triggering death of liver tumor cells in the rabbit VX2 implantation model . Antisense approaches to knockdown hexokinase II protein and hydrophobic peptides that compete with hexokinase II for binding sites on the mitochondria are promising strategies under evaluation.
A summary of the compounds described in this section is presented in Table 1 .
Agents that exploit bioenergetic and metabolic alterations of tumor mitochondria
Compounds that are sensitive to differences in mitochondrial membrane potential One of the most common tumor phenotypes is the alteration of glucose metabolism. Normal cells produce most of the ATP from glucose through oxidative phosphorylation (OXPHOS). Mitochondria generate ATP by dissipating the proton gradient generated across the inner mitochondrial membrane as electrons are pumped across the respiratory chain. On the other hand, cancer cells produce most of their ATP by glycolysis. Tumor cells in general exhibit reduced OXPHOS activity, which coincides with a smaller dissipation of the mitochondrial proton gradient (DmH þ ). The buildup of the proton gradient may contribute to the elevated mitochondrial membrane potential (Dc m ) observed in a variety of carcinoma cells. In addition, factors including high ATP/ADP and high NADH/NAD þ ratios due to inhibition of ATP synthase activity and elevated concentration of respiratory chain substrates could also play a role. It is beyond the scope of this review to discuss this area in detail (for the interested reader, please refer to Chen, 1988; Kadenbach, 2003) . The difference in Dc m detectable between normal and malignant cells is at least 60 mV. Delocalized lipophilic cations (DLCs) are a family of compounds that accumulate in mitochondria driven by the negative transmembrane potential. Some DLCs are sensitive to the higher Dc m in malignant cells, and selectively accumulate in their mitochondria (Summerhayes et al., 1982; ModicaNapolitano and Aprille, 2001 ). For instance, lipophilic 99m Tc complexes used for tumor imaging belong to this category (Moretti et al., 2005) . Molecules of this class share a hydrophobic structure and a delocalized positive charge, which together allow DLCs to cross lipid membranes and favor their accumulation in the mitochondria, as a consequence of the negative transmembrane potential. At high concentrations, these molecules are toxic to mitochondria resulting in tumor cell death. Members of the DLC family are structurally diverse, and not surprisingly their mitochondrial targets are quite different. The anticarcinoma activity of the prototype DLC rhodamine 123 (Rh 123) has been associated with its inhibitory effect on F 0 -F 1 ATPase (Anderson et al., 1989) . The mitochondriotoxic activity of the pyridinium derivative F16, identified in a highthroughput screen for selective inhibitors of HER-2/ Neu-overexpressing breast cancer cells, has been linked to its ability to dissipate the proton gradient across the inner mitochondrial membrane (Fantin et al., 2002) . Rhodocyanine MKT-077 activity has been associated with an effect on mitochondrial membranes and mitochondrial DNA (Modica-Napolitano et al., 1996; Chiba et al., 1998) . The antitumor effect of MKT-077 in xenografted mice models along with its selective accumulation in tumor mitochondria prompted its evaluation in the clinic. Owing to renal toxicity encountered during the Phase I trial, development of MKT-077 was discontinued (Propper et al., 1999; Britten et al., 2000) .
It is important to emphasize that both studies established preferential accumulation of MKT-077 in mitochondria of cancer cells, providing proof-of-concept in men for this chemical class. One of the major obstacles to the development of DLC is their structural heterogeneity. Each DLC represents a unique case study, as the potential liabilities of one may not be relevant to others. Moreover, our understanding of the structural determinants that confer tumor selectivity to each DLC is still limited. Nevertheless, recently two models based on the lipophilicity/hydrophilicity ratio, the acid/base dissociation constant and polarity of DLCs have been proposed to discriminate those with high affinity for tumor cell mitochondria from the nonselective, toxic ones (Kandela et al., 2003; Trapp and Horobin, 2005) . Such approaches may help to construct focused DLC libraries of compounds with increased selectivity for tumor cells. Based on the general mechanism of action of most DLCs, combination strategies that may lead to enhanced anticarcinoma activity could be envisioned. As these compounds interfere with mitochondrial respiration, inhibitors of glycolysis may synergize with them. Indeed, treatment of osteosarcoma cells with Rh123 sensitized them to 2-deoxyglucose and oxamate (Liu et al., 2001) . Alternatively, agents that decrease the redox buffer capacity of mitochondria, such as L-buthionine-sulfoximine may contribute to enhance the oxidative stress created by treatment of tumors cells with DLCs.
Another promising application of lipophilic cations is as photosensitizer molecules for photochemotherapy. Some DLC can be activated by light into highly reactive and toxic species. Their accumulation in mitochondria of cancer cells mediates the photochemically activated toxicity with high degree of selectivity (Lacerda et al., 2005) . Cationic photosensitizers are being evaluated as a form of treatment for a variety of neoplasms.
The mitochondria targeting properties of DLCs are also being used to target bioactive molecules to this organelle. In the 1980s, an attempt was made to complex a platinum compound to Rh123 (Teicher et al., 1986) . The platinum-Rh123 complex displayed some degree of selectivity toward transformed cells. However, the design was not optimal: the final complex had a neutral net charge, which compromised its ability to accumulate in the mitochondria. The rather unselective triphenylphosphonium (TPP) was conjugated to coenzyme Q and a derivative of vitamine E as a means to target antioxidant compounds to sites under high oxidative stress to prevent tissue degeneration (Smith et al., 2003) . These antioxidant compounds displayed good oral bioavailability in mice. Unlike the platinum-Rh123 complex, the TPP-conjugate accumulated in mitochondria of a variety of tissues. These examples indicate that by choosing the appropriate DLC and carefully designing the conjugation strategy, it may be possible to deliver toxins selectively to mitochondria of tumor cells. A novel mitochondria delivery system is based on dequalinium. This DLC forms liposome-like aggregates termed 'DQAsomes'. DQAsomes are being tested as mitochondria drug delivery systems for small molecules such as paclitaxel (Weissig et al., 2004) .
Compounds selectively toxic to reactive oxygen species-stressed malignant cells Reactive oxygen species (ROS) are produced by various organelles within cells, with a prominent role for mitochondria. They participate in the regulation of physiological processes such as proliferation and migration, but their excess has been associated with several pathological states (Kirkinezos and Moraes, 2001) . Within mitochondria, the electron transport chain is a major source of ROS production. Electrons flow down the gradient of redox potential through the respiratory complexes to the final acceptor, oxygen. During this process, electrons that leak at the level of Complex I (NADH-ubiquinone oxidoreductase) and Complex III (ubiquinone-cytochrome c oxidoreductase) react with oxygen to produce superoxide. Cancer cells are generally under increased oxidative stress presumably because of the increased rate of proliferation, deregulation of cellular metabolism and alterations in the balance of pro-and antioxidants. It is widely believed that the alteration of the redox environment of the cell cooperates in the process of malignant transformation by promoting DNA damage and genomic instability, by stimulating proliferation and survival as well as by affecting the response to radiation and chemotherapy (reviewed by Pelicano et al., 2004) . As a consequence of the elevated ROS stress, cancer cells adapt by upregulating antioxidant mechanisms (both enzymes like manganese-dependent superoxide dismutase (MnSOD) and cofactors such as reduced glutathione) involved in free radical detoxification. Thus, cancer cells could be viewed as metastable systems that heavily rely on their antioxidant buffering capacity due to their inherent tendency to produce high levels of ROS. There are two potential ways to exploit this situation from the cancer therapeutic perspective. As cancer cells are operating under persistent oxidative stress, the threshold to tip the balance towards induction of cell death by increasing the oxidative burden is usually lower. A number of conventional cancer therapies (radiation, cisplatin, anthracyclines) are based on this premise. Arsenic trioxide belongs to the category of compounds that stimulate oxidative stress. In addition to the effect on the PTP complex previously discussed, arsenic trioxide interferes with mitochondrial electron transport leading to an increase in ROS levels and concomitant cancer cell death. The annonaceous acetogenins (ACG) are a family of natural products that inhibit electron transport at the level of Complex I. In particular, the natural bistetrahydrofuranic acetogenins (THF ACG) and semisynthetic derivatives show growth inhibitory activity against human breast, lung, liver and colon cell lines (Chahboune et al., 2006) . More recently, SAR analysis has led to the synthesis of promising new derivatives with improved antitumor properties.
One caveat to the use of agents aimed at disrupting the redox balance by increasing production of ROS levels is that in some instances the adaptation that cancer cells undergo to cope with persistent oxidative stress renders them highly resistant to these therapeutic modalities. An alternative strategy to circumvent such limitation is to target antioxidant enzymes involved in ROS detoxification. The family of superoxide dismutases encompasses a group of enzymes that are involved in metabolizing superoxide radicals to hydrogen peroxide which is in turn metabolized by enzymes such as catalase and glutathione peroxidase to less reactive species such as H 2 O and O 2 . The mitochondrial isoform, MnSOD is a target of the natural estrogen metabolite 2-methoxyestradiol (2-ME), which is devoid of estrogenic effects. In preclinical studies 2-ME exhibited selective cytotoxicity for leukemia cells in comparison to normal lymphocytes (Huang et al., 2000) . In this case, the activity of 2-ME was associated to an increase in superoxide levels resulting in mitochondrial membrane damage and induction of p53-independent apoptosis. This compound is currently in Phase II clinical trials for the treatment of multiple myeloma and solid tumors. Encouraging results are beginning to emerge also from preclinical studies designed to test the antitumor effects of ROS-producing agents in combination with inhibitors of antioxidant enzymes or compounds that decrease levels of reduced glutathione (Pani et al., 2004) . This combination strategy may prove useful against a wide range of cancers. For the reader's convenience, a summary of the compounds described in Section 2 is provided (Table 1) .
Agents to attack mitochondrial DNA
Another peculiar feature of mitochondria is that they contain DNA (Nass and Nass, 1963; Kang and Hamasaki, 2005) . Most of the mitochondrial proteins are encoded by the nuclear DNA. However, the mitochondrial genome carries the information for 13 proteins essential for proper respiration, as well as for the mitochondrial transcription and translation machinery. Unlike the nuclear genome, the mitochondrial DNA (mtDNA) is not protected by histones, which makes it more susceptible to damage. In addition, the DNA repair capacity of mitochondria is limited. These characteristics of mtDNA make it an attractive target for DNA-damaging therapies. Intentionally targeting mtDNA for therapeutic purposes is an area that has just began to be explored. There is evidence in the literature indicating that several standard chemotherapeutic agents lead to mtDNA damage (Andre et al., 2002) . In fact, dose-limiting toxicities of several compounds in this class have been linked to effects on mtDNA (Singh et al., 1992) . However, it is unclear what the contribution of the mtDNA damage often viewed as a 'toxic side effect' is to their therapeutic efficacy. Adriamycin treatment of HeLa cells has been shown to induce mtDNA deletions (Singh et al., 1999) . The resistance of Rho0 derivatives, devoid of mitochondrial DNA, to adriamycin suggested that mitochondrial DNA played a role in determining response to this anthracycline. Recently, this question was revisited in the non-SCLC line A549 (Lo et al., 2005) . The results from this analysis indicated that the A549 Rho0 line was resistant to the anthracycline daunorubicin as well as the DNA-interacting lipophilic cation MKT-077. This data provides direct evidence that targeting mtDNA could indeed have therapeutic implications. Additional studies will be helpful to clarify whether nonanthracycline DNA damaging agents behave in a similar way. As previously mentioned, attempts were made to deliver platinum compounds to mitochondria of cancer cells by conjugation to DLCs. The relative success of the approach was most likely due to the unusual design of the chimeric molecule. Careful evaluation of the conjugation strategy (i.e. charge of the cytotoxin should not neutralize the positive charge of the DLC or profoundly alter its lipophilicity), or use of encapsulation in DLC-derived liposomes to selectively deliver DNA damaging agents to tumor mitochondria may represent an effective therapeutic approach.
Mitochondriotoxic conjugates with selective antitumor activity
Today the challenge to defeat cancer does not lie any longer in the identification of potent cytotoxic agents but rather in the discovery or design of molecular entities with selective antitumor activity (reviewed by Kaelin, 2005) . As highlighted in previous sections, tumor cell mitochondria exhibit unique hallmarks that per se offer interesting ground for the development of novel and selective anticancer therapeutics. However, approaches that enable the delivery of mitochondriotoxic agents to malignant cells with a high degree of specificity represent an additional strategy to improve the therapeutic index of compounds for the treatment of cancer (Figure 3) . Two extreme scenarios could be considered. On one side, this approach may facilitate the delivery of plasma membrane impermeable mitochondriotoxic agents that unless targeted through a receptor would not reach the organelle inside the cells. On the other hand, targeted delivery may confer tumor selectivity to rather unselective mitochondriotoxins that would otherwise target as well mitochondria in normal tissue. Over the last 6 years examples of targeted mitochondriotoxic compounds have begun to emerge. For instance, a series of peptides that selectively affect mitochondria of angiogenic endothelial and tumor cells were derived by conjugation of synthetic mitochondriotoxic peptides to tumor-targeting domains. These synthetic peptides were derived from naturally occurring lytic peptides secreted by multicellular organisms as an innate defense mechanism against pathogens (Bulet et al., 2004) . Probably the most studied are the family of cationic amphipathic a-helical peptides (Epand et al., 1995) . They exert their toxicity by permeabilizing lipid membranes rich in acidic phospholipids, like those found in bacteria. Most normal eukaryotic cell membranes are mainly composed of zwitterionic phospholipids and contain cholesterol, which prevents permeabilization and protects cells from lysis. The amphipathic nature of the cationic peptide is thought to drive the alignment of the positive peptide surface with negatively charged membranes. This interaction affects the electroelastic properties of the membranes resulting in disruption of the membrane structure. To reduce the hemolytic activity and increase the antimicrobial properties of cationic peptides a series of derivatives were synthesized using a repetitive heptad approach (Javadpour et al., 1996) . Not surprisingly, some of the peptides that showed increased selectivity towards bacterial membranes, displayed activity towards mitochondrial membranes in cell-free assays (Ellerby et al., 1997) . Their low toxicity toward mammalian cells is due to their inability to efficiently cross the plasma membrane. However, when coupled to a targeting domain the synthetic cationic amphipathic peptide is internalized and reaches the mitochondrial membranes, where it ultimately triggers death of the target cell. The conjugation to a targeting domain was successfully used to direct the proapoptotic (KLAKLAK) 2 peptide to the mitochondria of angiogenic endothelial cells and vasculature of white fat (Ellerby et al., 1999; Kolonin et al., 2004) . More recently, we exploited the high levels of the tyrosine kinase receptor HER-2 frequently found in breast cancer cells to selectively deliver a protease-resistant version of (KLAKLAK) 2 to their mitochondria. A bifunctional peptide, BHAP, was created by fusing a HER-2 binding and neutralizing domain to the mitochondriotoxic peptide (Fantin et al., 2005) . BHAP-triggered apoptosis of HER-2-overexpressing breast cancer cells in vitro and in vivo. In fact, HER-2 overexpression was sufficient to render multidrug resistant MDA-MB-231 sensitive to BHAP. Also the luteinizing hormone-releasing hormone (LHRH) was used to target a BH3 proapoptotic peptide to tumor cell lines overexpressing the hormone receptor (Dharap and Minko, 2003) . The LHRH-BH3 fusion peptide was shown to induce apoptosis of human cancer cell lines, and the response correlated with the level of expression of the LHRH receptor in the set of cell lines tested. The effect of LHRH-BH3 was blocked by the control LHRH peptide, confirming that BH3 uptake indeed occurs via a receptor-mediated mechanism. Mastoparan, an amphipathic peptide obtained from wasp venom, is a potent inducer of mitochondrial PT. However, mastoparan is equally toxic for malignant and normal cells. To overcome this limitation, mastoparan was encapsulated into a tumor-selective delivery system (Yamada et al., 2005) . The peptide was delivered to mitochondria of leukemia cells by transferrinmodified liposomes containing a pH-sensitive fusogenic peptide (GALA) to maximize endosomal escape. The results are encouraging and further studies are underway to evaluate the selectivity and antitumor activity of the system. Targeted delivery to mitochondria is an area in its infancy, and some of the agents discussed are still in the early days of development. The examples discussed suggest that tailored medicines for the treatment of cancer may indeed be possible. The array of overexpressed receptors often observed in tumors and the availability of high-affinity peptides against them present us with a unique opportunity to customize the delivery of mitochondriotoxic peptides and/or small molecules to specific tumor cell populations.
Concluding remarks
The progress made in our understanding of the central place of mitochondria as a regulator of cell death and of its role in the pathogenesis of cancer has launched the academic community, as well as biotechnology and pharmaceutical industry in the search for new opportunities for therapeutic intervention. The list of compounds Figure 3 Mitochondria-targeted conjugates with selective antitumor activity. Overexpression of cell surface receptors has been described for a number of cancers. One approach to increase the selectivity of mitochondriotoxic compounds is through their conjugation to ligands for these tumor-overexpressed receptors. The resulting chimeric tumor-targeted mitochondriotoxin (T-Mtx) is selectively internalized by malignant cells, sparing normal cells that do not express significant levels of the receptor. designed to target mitochondria is extensive and keeps on growing. As these compounds progress through the drug development pipeline, lessons are learned about their strengths, their liabilities and the opportunities for improvement of these potential therapeutic entities. Ultimately, it is from this iterative process that novel mitochondriotxic compounds with improve selectivity for tumor cells will continue to emerge.
